FiercePharma

AstraZeneca's first-in-class rescue inhaler Airsupra wins FDA nod—but only for adult use

As AstraZeneca fights to defend its aging two-drug inhaler Symbicort against generics, the company has a new approval to bolster its respiratory business. Wednesday, the British drugmaker said the FDA ...
abc27

AstraZeneca follows rival, will cap inhaler prices at $35 per month amid scrutiny

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s entire ...
Healio

KALOS, LOGOS: Triple therapy inhaler improves lung function in asthma

Please provide your email address to receive an email when new articles are posted on . Two doses of budesonide/glycopyrrolate/formoterol fumarate improved lung ...
FiercePharma

Viatris prevails in another patent feud over AZ's blockbuster asthma med Symbicort

In the courtroom fracas over the patents on AstraZeneca’s multibillion-dollar inhaler Symbicort, Viatris and Kindeva Drug Delivery have toppled yet another intellectual property pillar. Still, ...
WDAF-TV

AstraZeneca follows rival, will cap inhaler prices at $35 per month amid scrutiny

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker AstraZeneca will cap ...